Infinitopes

INFINITOPES GOES CLINICAL - PHASE I/IIA APPROVED TO BEGIN ✨ We’re delighted to share that Infinitopes has received Clinical Trial Application (CTA) approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a ground-breaking Phase I/IIa study of our lead investigational ‘off-the-shelf’ cancer vaccine, #ITOP1, for patients with early-stage oesophageal cancer. ✨ By combining safe and accurate synergistic tumour targets identified through our Precision Immunomics™ platform, with optimised delivery vectors, capable of stimulating durable T-cell responses, for patient populations and administration at the most effective time in their treatment journey, ITOP1 aims to address a critical unmet medical need. Oesophageal cancer remains challenging, ranked as the 6th leading cause of cancer-related death and the 12th most common cancer in the UK. ✨ Following our Innovation Passport award from the MHRA in 2022, patient recruitment for the VISTA study is scheduled to begin in Q2 2025. This trial will evaluate ITOP1's safety, tolerability, immunogenicity, and anti-tumour protection, with the goal of improving patient outcomes. ✨ Huge thanks to our exceptional team, committed partners, supportive investors, and expert advisors for their essential contributions to this milestone. Octopus Ventures, Cancer Research UK (CRUK), Cancer Research Horizons, Cancer Research Institute (CRI), Kindred Capital VC, Manta Ray Ventures, Meltwind Advisory LLP, Martlet, Saras Capital, Wilbe, CRIS Cancer Foundation, University of Oxford, the BioEscalator and expert angel investors. Stay tuned for more updates and click the link in the comments to read our full press release! 👇 https://lnkd.in/eeiysNpB #Infinitopes #biotech #biotechnology #CancerVaccines #oncology #ImmunoTherapies #ImmunoOncology #CancerResearchUK #OxfordUniversity #ClinicalTrials

INFINITOPES STRENGTHENS BOARD WITH TWO BIOTECH LEADERS We're delighted to welcome Daniel Menichella and Jo Brewer, PhD to the Board. Dan brings highly relevant commercial & scale-up expertise from his experience as CEO and CBO at CureVac US, winning major deals including a $1.7bn cancer vaccine collaboration with Eli Lilly. As CSO of Adaptimmune, Jo has grown a science team from 15 to more than 500 employees, navigating two exciting immuno-oncology products from bench to approvals. This is an extraordinary moment for Infinitopes, as we exploit the technical leadership of our Precision Immunomics™️ antigen discovery technologies, capable of discovering many more, validated, safe & accurate disease targets. Watch out for imminent announcements on the progress of our game changing, randomised, placebo-controlled, double-blind phase I/IIa human trial, soon to enter the clinic at four NHS university cancer centres. To protect patients from the recurrence of oesophageal cancer.   Welcome Dan & Jo! We're over the moon to have you with us.   And of course, enormous thank yous to our constant advisors, mentors & supporters Octopus Ventures, Cancer Research UK (CRUK), Cancer Research Horizons, Cancer Research Institute (CRI), Kindred Capital VC, Manta Ray Ventures, Meltwind Advisory LLP, Martlet, Saras Capital, Wilbe, CRIS Cancer Foundation, University of Oxford, the BioEscalator and expert angel investors.   Learn more about Dan & Jo, and our cancer vaccine development in our full press release here -> https://lnkd.in/eNCN6Uyp #biotech #CancerVaccines #oncology #ImmunoOncology #oxforduniversity #leadership

Are you finishing your STEM degree or dreaming of launching your own venture, but feel stuck on questions about tech spin-outs, IP structures, and navigating the biotech landscape? You're not alone. Join the Oxford Venture Capital Network at GSK and Stevenage on 20 February for a full-day event designed to tackle these challenges. Dive deep into topics like commercialising university research, exploring career paths in VC, and understanding the life sciences and biotech industries. Hear from leading industry experts, grow your professional network, and gain the tools to transform groundbreaking ideas into successful ventures. Get your tickets HERE 🎟️: https://lnkd.in/dEVYbcGm 🚌 Transport options are available Tagged Societies: GSK, OBN (UK) Ltd, Stevenage Bioscience Catalyst, LongeVC, Healthspan Capital, Ligo Biosciences, Shift Bioscience, TTP plc, Taylor Wessing, Taylor Wessing UK, Oxford Science Enterprises, Infinitopes In Partnership With: Oxford University Bioengineering Society UCL Engineering Society LSE SU Venture Capital Society Cambridge University MedTech Society Surgery and Interventional Science Society Imperial College Biochemistry Society Warwick BioSoc KCL Engineering Society UCL Medical Physics and Biomedical Engineering Society Cambridge University AI in Medicine Society Oxford University Synthetic Biology Society (SynBio.Oxford) Bristol Biomed Society Bath Entrepreneurs Science Entrepreneur Club National MedTech Foundation

Excited for our CEO Jonathan Kwok to share his thoughts and journey in taking us to the cusp of the clinic, and towards revolutionary cancer vaccine cures with Wilbe and the #Oxford and #UKinnovation ecosystem. If you're in the area, come along and meet + connect with us alongside some of the other innovative BioEscalator teams!

Today is #WorldCancerDay 🌍 Optimum is proud to support clients who are making groundbreaking advancements to improve the lives of patients suffering with cancer #UnitedbyUnique #OptimumStrategicCommunications

Join us at Biotech Showcase on Tuesday 1:30 PM to hear our CEO and co-founder Jonathan Kwok's vision for long-term cure of cancer, backed by Cancer Research UK (CRUK), Cancer Research Horizons and others. Discover how we're using #righttargets, #rightvector, #rightpatients and #righttime to make cancer vaccines that work. Franciscan D, Hilton Union Square. See you there.

📺 Our CEO and Co-Founder, Jonathan Kwok, is featured in the latest episode of #OptimumTV!   Watch below as Jonathan provides insights on our Precision Immunomics™ antigen discovery platform and its potential to accurately design best-in-class therapeutics for multiple #cancer indications. Stay tuned for further updates as we prepare to enter clinical development with our lead vaccine candidate ITOP1 in a Phase I/IIa clinical trial for the treatment of oesophageal cancer (OC).   #Infinitopes #PrecisionMedicine #Immunotherapy #CancerResearch #CancerVaccine

Had a great day at the #InnovationSummit24, Edinburgh organised by Cancer Research Horizons. Thanks to Phil Masterson for chairing the panel discussion on “Charting the pathways to patient impact: the role of start-ups in oncology innovation” and co-speakers Clare Wareing, Ishani Malhotra and Tracy Weightman for sharing your insights.

Join Infinitopes at the Society for Immunotherapy of Cancer (SITC) Annual Meeting today in Houston, where we will be presenting our latest breakthroughs in cancer vaccine discovery and development.   Powered by our AI/ML Precision Immunomics™ antigen discovery platform, we can identify best-in-class pools of hundreds of novel cancer-specific antigens, to empower collaborator’s T-cell & TCR therapies, in addition to our vaccine pipeline. Our lead vaccine candidate ITOP1, is a precision-targeted, immunologically durable, “off-the-shelf” cancer vaccine, designed to prevent recurrence of oesophageal cancer (OC) in patients. ITOP1 has the potential to offer a transformative approach to cancer treatment and will be entering Phase I/IIa clinical development (VISTA study) in H1 '25.    We will be presenting three posters on our pioneering cancer vaccine discovery and development on 8 November, 9am – 7pm CDT:   🔬 Poster #635: ‘A randomised, placebo-controlled, multi-centre Phase I/IIa study evaluating the safety and clinical activity of a novel viral vector cancer vaccine (ITOP1) in patients with resectable oesophageal adenocarcinoma (VISTA study)’ 👩🔬 Poster #1039, recognised as a SITC Top 100 poster: ‘Vaccination with a single dose of a novel delivery platform confers durable >8 month immune responses, with lasting protection against tumour and metastases in preclinical models’ ⚕ Poster #1427: ‘Precision Immunomics™: Identification of hundreds of novel cancer antigens using a sensitive immunopeptidomics-led platform’   Using our integrated ‘right targets, right vectors, right patients, right time’ approach, we are excited to share our latest research as we aim to address unmet clinical need using durably effective therapies to save lives by preventing or significantly delaying disease recurrence for cancer patients.   For more details on our world-leading platforms in precision antigen discovery with vaccine vectors, you can find the full press release on our website and in the comments below.   #Infinitopes #PrecisionMedicine #SITC2024 #Immunotherapy #CancerResearch #CancerVaccine